Biohaven

Initial read: cautious, but more interesting after the balance-sheet reset. The SK Biopharmaceuticals deal makes strategic sense.

1. Biohaven exchanges most of opakalim's direct economics for cash—$350 million at closing, $50 million one year after closing and up to $150 million in milestones—plus retained royalties of mid-teens to low-twenties on U.S. sales. SK takes on future Kv7 development costs and commercial execution.
2. The deal also changes what shareholders own: on closing, BHVN becomes mainly a cash-funded set of earlier programs, led by extracellular protein degraders, with an opakalim royalty attached. Financing pressure falls, but it does not go away.
3. Pro-forma cash is roughly $620 million after the closing payment. That sits against $259.5 million of notes and a quarterly operating-expense run-rate of approximately $125 million in 2Q26.
4. The simple comparison is equivalent to about five quarters of 2Q operating expense, although it is not a formal runway calculation because operating expense includes non-cash items and actual cash use will vary. It does not reach a disclosed Graves' Phase 3 readout.
5. Biohaven also leaned heavily on its ATM in 1H26, issuing 17.2 million shares for $179 million of net proceeds, so further dilution belongs in the base case. The partial clinical hold does not stop RISE3: the trial is fully enrolled and still reads out in 2H26.
6. The hold does stop RISE2 recruitment. That could delay a filing even if RISE3 is positive because the program was built around two pivotal trials.
7. The hold also adds uncertainty to closing, which still awaits HSR clearance, even if the metabolite proves rodent-specific. The degraders are scientifically more interesting than their datasets are mature.
8. BHV-1300 produced a greater than 80% mean reduction in pathogenic TSHR-IgG1 by Week 12 in a small Phase 1b, while BHV-1400 lowered Gd-IgA1 by approximately 70% within one month. Both datasets are small, open-label and uncontrolled.
9. The Graves' Phase 3 is the first real efficacy test—approximately 300 patients, with Week-26 hormone normalization off antithyroid drugs—and Biohaven has not given a topline date. Taldefgrobep adds a 2H26 obesity readout.
10. Scale weight and body composition should be kept separate from functional benefit, especially after the SMA Phase 3 missed its primary motor-function endpoint. At approximately $1.56 billion of pro-forma enterprise value using the June balance sheet and $350 million closing payment before 3Q burn, BHVN is better financed but not obviously cheap.
11. Most of that value has to come from programs that have not yet shown controlled clinical efficacy.